Two shots that protect against Ebola virus yielded immune responses lasting for at least a year, according to a study suggesting they might keep the virus at bay for the long-term.
Researchers studied the vaccines, one from Merck & Co. and a two-dose regimen from Johnson & Johnson and Bavarian Nordic A/S, in 1400 adults and 1401 children enrolled from April to December 2018, according to a report from the Partnership for Research on Ebola Vaccinations research consortium.
Ebola has been a thorn in the side of health officials as it continues to emerge unpredictably in African countries.
The World Health Organization is working with Uganda to fight a vaccine-resistant Ebola strain called Sudan that’s caused more than 140 confirmed cases and 55 deaths there.
